| Abstract: | The rate of control of hypertension remains suboptimal despite widespread educational programs and an increasing number of novel medications. The combination of drugs with different mechanisms of action has become an alternative to improve blood pressure reduction and control, enhance adherence to the treatment and reduce adverse events. Telmisartan and amlodipine in monotherapy provide effective blood pressure lowering at all clinically relevant doses, but less than 50% of stage 1 and 2 achieve the target blood pressure. This article presents most of the relevant results of combinations of telmisartan plus amlodipine, at different doses, in hypertensive patients and a post hoc analysis of subgroups including the elderly, Type 2 diabetics, those with systolic hypertension and obese patients. |
